Kyverna Therapeutics, Inc. (KYTX) earnings date
Mar 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 43 days, typically, give or take 20 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | before open | 43 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | after close | 42 | 8-K |
| Q1 FY2026 | Tue, May 12, 2026 | after close | 42 | 8-K |
| Q4 FY2025 | Thu, Mar 26, 2026 | after close | 85 | 8-K |
| Q3 FY2025 | Wed, Nov 12, 2025 | after close | 43 | 8-K |
| Q2 FY2025 | Tue, Aug 12, 2025 | after close | 43 | 8-K |
| Q1 FY2025 | Tue, May 13, 2025 | after close | 43 | 8-K |
| Q4 FY2024 | Thu, Mar 27, 2025 | after close | 86 | 8-K |
What they guided beta
| Q3 FY2026 | "The primary analysis from KYSA-8 were recently published in the Journal of American Medical Association (JAMA) Neurology , and additional one-year biomarker data from KYSA-8 will be presented at ASH 2026." exhibit |
| Q3 FY2026 | "In addition, miv-cel demonstrated a consistent and well-tolerated safety profile with no high-grade CRS, no ICANS, and no reported cases of IEC-HS. o The robust longer-term follow up data continue to de-risk the Phase 3 gMG trial, with enrollment expected to be completed in mid-2027." exhibit |
| Q3 FY2026 | "Kyverna expects to share its development strategy in PMS by early 2027." exhibit |
| Q3 FY2026 | "Kyverna reported $170.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which, in addition to amounts available for draw from the Oxford Finance amended loan facility, is expected to provide operating runway into 2028." exhibit |
| Q2 FY2026 | "Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy’s potential across neuroimmunology On track to complete rolling BLA submission for miv-cel in stiff person syndrome (SPS) in Q4 2026; KYSA-8 12-month topline data expected in Q3 2026 Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data e" exhibit |
| Q2 FY2026 | "SPS Rolling Biologic License Application (BLA) Submission Underway and Commercial Readiness Activities On-Track : o Kyverna has initiated its rolling BLA, submitted the Chemistry, Manufacturing and Controls (CMC) module and is on track to complete its submission in the fourth quarter of 2026. o The Company plans to seek priority review, under the Regenerative Medicine Advanced therapy (RMAT) designation, positioning miv-cel for potential commercial launch in 2027. o Kyverna continues to advance activities to enable a successful rare disease launch in SPS upon approval." exhibit |
| Q2 FY2026 | "Enrollment Ongoing in KYSA-6 Registrational Trial for gMG: o Kyverna continues to advance its Phase 3 gMG trial and expects to complete enrollment by mid-2027." exhibit |
| Q2 FY2026 | "The Company anticipates sharing longer-term follow-up Phase 2 topline data in Q3 2026." exhibit |
| Q2 FY2026 | "This designation provides the opportunity for increased FDA engagement and eligibility for priority and rolling reviews, as well as accelerated approval pathways, with the goal of bringing transformative innovations to patients more quickly. o Kyverna expects to provide an update on its PMS development strategy by early 2027, as well as additional data from the Stanford Phase 1 IIT in Q4 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/KYTX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/KYTX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/KYTX/"><img src="https://veritasdata.dev/embed/KYTX.svg" alt="KYTX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/KYTX/)
Script
<script async src="https://veritasdata.dev/embed/KYTX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/KYTX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.